AHAtticus Henry Hainsworth

Atticus Henry Hainsworth

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Atticus Henry Hainsworth has a total of 585 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The vascular contribution to dementia: World Stroke Organization scientific statement

    by Geert Jan Biessels, Stephanie Debette, Fanny M Elahi, Fatemeh Geranmayeh, Gurpreet K Hansra, Timothy M Hughes, Masafumi Ihara, Jeremy D Isaacs, Hanna Jokinen, Alexi Nott, et al.

    Background: Alzheimer’s disease (AD) and cerebrovascular pathology are the two most common causes of dementia, frequently co-occurring in older people. Community-based neuropathology studies indicate that vascular disease accounts for approximately one-third of the population-attributable risk of dementia, controlling for other pathologies (including AD). The proportion with vascular disease as co-pathology is likely to be higher (50–70%). The most common vascular substrate is cerebral small vessel disease, which includes small artery fibrosis (arteriolosclerosis), vascular amyloid deposits (cerebral amyloid angiopathy), and monogenic forms of small vessel disease, the commonest being Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Post-stroke cognitive impairment following both ischemic stroke and intracerebral hemorrhage also contributes. Aims and Methods: In this World Stroke Organization (WSO) scientific statement, we assembled a multi-disciplinary international group of experts to review the vascular contribution to dementia, encompassing both vascular and neurodegenerative dementia. This statement has been reviewed and approved by the WSO executive. Results: We summarize the epidemiology, neuropathology, cognitive profile, clinical impact and management of vascular disease in dementia and discuss the recent VasCog-2-WSO diagnostic criteria. We consider the substantial overlap with clinical stroke and with AD dementia. We catalog transcriptomic and proteomic studies that have revealed novel candidate molecules ( COL4A1/4A2, HTRA1, TRIM47, FOXF2 ) as possible treatment targets. We appraise imaging-based biomarkers relevant to vascular disease and potential biochemical markers (vascular endothelial growth factor-A, placental growth factor, interleukin-6, matrix metalloproteinase-9, cathepsin-B). We highlight the potential for vascular interventions to treat not only vascular dementia but also the vascular component of neurodegenerative dementia. We review recent clinical trials targeting multiple pathways, including nitric oxide signaling, high blood pressure, the GABAergic system, angiogenic activity, microglial inhibition, PDE3 and PDE5 inhibition, as well as dietary supplementation with omega-3 fatty acids, s-equol and vitamin E. Finally, we consider upcoming opportunities and challenges relevant to vascular disease in dementia. Conclusion: The vascular contribution to dementia is i) substantial, ii) increasingly understood at molecular and mechanistic levels, iii) a source of potential treatment opportunities. Data Access Statement: no original data are presented in this document.


  • Open Access

    Transgenic Domestic Pigs for research in Vascular Contributions to Cognitive Impairment and Dementia

    by Atticus H Hainsworth, Love Onwuzuruike, Misha Ramesh, Raimondo Ascione, Colin Berry, Leslie Bridges, Diana Cash, Eddie Clutton, Carola Daniel, Betty Gao, et al.

    Background: Cardiovascular disease causes vascular dementia and contributes to most clinical dementia. This is embodied in the concept of vascular contributions to cognitive impairment and dementia (VCID). The potent endogenous peptide endothelin‐1 (ET1) causes small artery vasoconstriction and fibrosis. ET1 is implicated in microvascular disease and in VCID. There are few experimental animal models relevant to VCID [Hainsworth et al. 2017]. Pigs are higher mammals with a gyrencephalic brain and extensive subcortical white matter.Method: We engineered domestic pigs carrying additional copies of the ET1‐encoding gene EDN1 under a Tet‐ON promotor, by lentiviral injection into blastocysts. We induced transgene expression for up to 8 days using oral doxycycline in young adults.Result: We studied ET1‐overexpressing (n = 6, 3F/3M, mean±SD age 184±61 days) and control animals (n = 5, 3F/2M, 149±41 days). Following doxycycline treatment we observed a wide range of transgene expression at mRNA level. Antibody labelling indicated a spectrum of ET1 abundance in brain and heart tissue. Heart weight was 460±106 g in ET1‐overexpressing pigs and 394±25 g in controls. Brain weight: 104±14.4 g in ET1‐overexpressing, 101±9.0 in controls. We will report phenotypes relevant to inflammation and blood vessel fibrosis.Conclusion: Adult‐onset EDN1 induction in domestic pigs produces ET1 overexpression that is well‐tolerated to 8 days.Reference: Hainsworth AH, et al. (2017) BMC Med.15(1):16. Translational models for vascular cognitive impairment: a review including larger species.

  • Open Access

    Editorial. CCCB: The journal at age 5

    by Atticus H Hainsworth, Riccardo Paracampo, Anders Wallin

  • Open Access

    The promise of molecular science in brain health. What breakthroughs are anticipated in the next 20 years?

    by Atticus H Hainsworth, Thomas P Blackburn, Elizabeth M Bradshaw, Fanny M Elahi, Philip B Gorelick, Jeremy D Isaacs, Anders Wallin, Steven Cr Williams


  • Top Cited Papers
    Open Access

    Cerebral Small Vessel Disease, Hypertension, and Vascular Contributions to Cognitive Impairment and Dementia

    by Atticus H. Hainsworth, Hugh S. Markus, Julie A. Schneider

    Hypertension-associated cerebral small vessel disease is a common finding in older people. Strongly associated with age and hypertension, small vessel disease is found at autopsy in over 50% of people aged ≥65 years, with a spectrum of clinical manifestations. It is the main cause of lacunar stroke and a major source of vascular contributions to cognitive impairment and dementia. The brain areas affected are subcortical and periventricular white matter and deep gray nuclei. Neuropathological sequelae are diffuse white matter lesions (seen as white matter hyperintensities on T2-weighted magnetic resonance imaging), small ischemic foci (lacunes or microinfarcts), and less commonly, subcortical microhemorrhages. The most common form of cerebral small vessel disease is concentric, fibrotic thickening of small penetrating arteries (up to 300 microns outer diameter) termed arteriolosclerosis. Less common forms are small artery atheroma and lipohyalinosis (the lesions described by C. Miller Fisher adjacent to lacunes). Other microvascular lesions that are not reviewed here include cerebral amyloid angiopathy and venous collagenosis. Here, we review the epidemiology, neuropathology, clinical management, genetics, preclinical models, and pathogenesis of hypertensive small vessel disease. Knowledge gaps include initiating factors, molecular pathogenesis, relationships between arterial pathology and tissue damage, possible reversibility, pharmacological targets, and molecular biomarkers. Progress is anticipated from multicell transcriptomic and proteomic profiling, novel experimental models and further target-finding and interventional clinical studies.


  • Open Access

    Testing the cognitive effects of tadalafil. Neuropsychological secondary outcomes from the PASTIS trial

    by Mathilde Mh Pauls, Jessica Fish, Lauren R Binnie, Philip Benjamin, Shai Betteridge, Brian Clarke, Mohani-Preet K Dhillon, Rita Ghatala, Fearghal Ah Hainsworth, Franklyn A Howe, et al.


  • Open Access

    PDE5 inhibitor drugs for use in dementia

    by Atticus H. Hainsworth, Ottavio Arancio, Fanny M. Elahi, Jeremy D. Isaacs, Feixiong Cheng

    Alzheimer's disease and related dementias (ADRD) remain a major health‐care challenge with few licensed medications. Repurposing existing drugs may afford prevention and treatment. Phosphodiesterase‐5 (PDE5) is widely expressed in vascular myocytes, neurons, and glia. Potent, selective, Food and Drug Administration–approved PDE5 inhibitors are already in clinical use (sildenafil, vardenafil, tadalafil) as vasodilators in erectile dysfunction and pulmonary arterial hypertension. Animal data indicate cognitive benefits of PDE5 inhibitors. In humans, real‐world patient data suggest that sildenafil and vardenafil are associated with reduced dementia risk. While a recent clinical trial of acute tadalafil on cerebral blood flow was neutral, there may be chronic actions of PDE5 inhibition on cerebrovascular or synaptic function. We provide a perspective on the potential utility of PDE5 inhibitors for ADRD. We conclude that further prospective clinical trials with PDE5 inhibitors are warranted. The choice of drug will depend on brain penetration, tolerability in older people, half‐life, and off‐target effects. HIGHLIGHTS: Potent phosphodiesterase‐5 (PDE5) inhibitors are in clinical use as vasodilators. In animals PDE5 inhibitors enhance synaptic function and cognitive ability. In humans the PDE5 inhibitor sildenafil is associated with reduced risk of Alzheimer's disease. Licensed PDE5 inhibitors have potential for repurposing in dementia. Prospective clinical trials of PDE5 inhibitors are warranted.


  • Open Access

    Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective

    by Fanny M. Elahi, Suvarna Alladi, Sandra E. Black, Jurgen A.H.R. Claassen, Charles DeCarli, Timothy M. Hughes, Justine Moonen, Nicholas M. Pajewski, Brittani R. Price, Claudia Satizabal, et al.


  • Open Access

    Vascular Collagen Type-IV in Hypertension and Cerebral Small Vessel Disease

    by Apoorva A. Kumar, Natalie Yeo, Max Whittaker, Priya Attra, Thomas R. Barrick, Leslie R. Bridges, Dennis W. Dickson, Margaret M. Esiri, Chad W. Farris, Delyth Graham, et al.

    Background: Cerebral small vessel disease (SVD) is common in older people and causes lacunar stroke and vascular cognitive impairment. Risk factors include old age, hypertension and variants in the genes COL4A1/COL4A2 encoding collagen alpha-1(IV) and alpha-2(IV), here termed collagen-IV, which are core components of the basement membrane. We tested the hypothesis that increased vascular collagen-IV associates with clinical hypertension and with SVD in older persons and with chronic hypertension in young and aged primates and genetically hypertensive rats. Methods: We quantified vascular collagen-IV immunolabeling in small arteries in a cohort of older persons with minimal Alzheimer pathology (N=52; 21F/31M, age 82.8±6.95 years). We also studied archive tissue from young (age range 6.2–8.3 years) and older (17.0–22.7 years) primates ( M mulatta ) and compared chronically hypertensive animals (18 months aortic stenosis) with normotensives. We also compared genetically hypertensive and normotensive rats (aged 10–12 months). Results: Collagen-IV immunolabeling in cerebral small arteries of older persons was negatively associated with radiological SVD severity (ρ: −0.427, P =0.005) but was not related to history of hypertension. General linear models confirmed the negative association of lower collagen-IV with radiological SVD ( P P P P =0.029) but was not associated with hypertension. Genetically hypertensive rats did not differ from normotensive rats in terms of arterial collagen-IV. Conclusions: Our cross-species data provide novel insight into sporadic SVD pathogenesis, supporting insufficient (rather than excessive) arterial collagen-IV in SVD, accompanied by matrix remodeling with elevated fibrillar collagen deposition. They also indicate that hypertension, a major risk factor for SVD, does not act by causing accumulation of brain vascular collagen-IV.